This article is more than 5 years old. Information may no longer be current.

Ophthotech completes patient recruitment for third phase 3 trial of Fovista

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ophthotech has completed patient recruitment for a phase 3 clinical trial of Fovista in combination with anti-VEGF agents for the treatment of wet age-related macular degeneration, according to a press release.

The three clinical trials in the phase 3 program are evaluating the safety and efficacy of Fovista (pegpleranib) in combination with anti-VEGF agents. The current third trial involves Fovista in combination with Eylea (aflibercept, Regeneron) or Avastin (bevacizumab, Genentech). The first two trials focused on Fovista in combination with Lucentis (ranibizumab, Genentech), and topline data are expected later this year.

As a result of reaching the patient enrollment goal, the company achieved a third $30 million enrollment milestone under its ex-U.S. licensing and commercialization agreement with Novartis.

Ophthotech will be eligible to receive up to an aggregate of $300 million upon achieving regulatory milestones, which include marketing approval and reimbursement approval in certain ex-U.S. territories and ex-U.S. sales milestones up to $400 million. The company will also be eligible to receive royalties on ex-U.S. Fovista sales.